Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001171843-22-004628
Filing Date
2022-06-30
Accepted
2022-06-30 06:00:12
Documents
9
Period of Report
2022-06-29

Document Format Files

Seq Description Document Type Size
1 FORM 6-K f6k_062922.htm 6-K 10204
2 EXHIBIT 99.1 exh_991.htm EX-99.1 7842
3 EXHIBIT 99.2 exh_992.htm EX-99.2 375649
4 EXHIBIT99.3 exh_993.htm EX-99.3 1537
5 EXHIBIT 99.4 exh_994.htm EX-99.4 5296
6 GRAPHIC logo.jpg GRAPHIC 9636
7 GRAPHIC proxy1.jpg GRAPHIC 87468
8 GRAPHIC proxy2.jpg GRAPHIC 152026
9 GRAPHIC perf.jpg GRAPHIC 30819
  Complete submission text file 0001171843-22-004628.txt   787601
Mailing Address SUITE 2400 - 745 THURLOW STREET VANCOUVER A1 V6E 0C5
Business Address SUITE 2400 - 745 THURLOW STREET VANCOUVER A1 V6E 0C5 403-607-2621
XORTX Therapeutics Inc. (Filer) CIK: 0001729214 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-40858 | Film No.: 221056402
SIC: 2834 Pharmaceutical Preparations